Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Amortization of Deferred Charges (2020 - 2023)

Journey Medical's Amortization of Deferred Charges history spans 4 years, with the latest figure at $177000.0 for Q3 2023.

  • For the quarter ending Q3 2023, Amortization of Deferred Charges fell 11.94% year-over-year to $177000.0, compared with a TTM value of $353000.0 through Dec 2023, down 54.16%, and an annual FY2023 reading of $353000.0, down 54.16% over the prior year.
  • Amortization of Deferred Charges for Q3 2023 was $177000.0 at Journey Medical, up from $78000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $804000.0 in Q2 2021, with the low at -$409000.0 in Q3 2021.
  • Average Amortization of Deferred Charges over 4 years is $175833.3, with a median of $189000.0 recorded in 2022.
  • Biggest YoY gain for Amortization of Deferred Charges was 149.14% in 2022; the steepest drop was 73.26% in 2022.
  • Tracing DERM's Amortization of Deferred Charges over 4 years: stood at $206000.0 in 2020, then fell by 19.9% to $165000.0 in 2021, then dropped by 8.48% to $151000.0 in 2022, then grew by 17.22% to $177000.0 in 2023.
  • Per Business Quant, the three most recent readings for DERM's Amortization of Deferred Charges are $177000.0 (Q3 2023), $78000.0 (Q2 2023), and $98000.0 (Q1 2023).